Literature DB >> 9034401

Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study.

E H Ludwig1, I B Borecki, R C Ellison, A R Folsom, G Heiss, M Higgins, J M Lalouel, M A Province, D C Rao.   

Abstract

Angiotensin-converting enzyme (ACE) and angiotensinogen (AGT) are major components of the renin-angiotensin systems. An association between myocardial infarction (MI) and the ACE DD genotype of the insertion/deletion (ID) polymorphism in intron 16 of the ACE gene has been reported. However, other similarly designed studies have not found such an association. Angiotensin II, the product of AGT, has a direct effect on vascular tone; and a variant in the AGT gene has been found to be associated with MI in the Japanese. This case-control study was initiated to investigate whether the ACEI/D and AGT M235T polymorphisms are associated with an increased risk for coronary heart disease (CHD) and MI. Our study groups were composed of participants in the National Heart Lung Blood Institute (NHLBI) Family Heart Study (FHS) selected from three population-based studies: two Atherosclerosis Risk in Communities (ARIC) centers (Forsyth County, NC, and Minneapolis, MN), and the Framingham Heart Study. In multivariate analysis within ARIC Caucasians, a significant positive association was found between CHD (controls = 230, cases = 232) and the AGT TT genotype (P = 0.022; OR = 1.84, 1.09-3.10 95% CI). When we restricted the analysis to a low-risk group for CHD (controls = 70, cases = 35) an interaction between the ACE DD and AGT TT genotypes was significant (P = 0.025; OR = 5.02 1.22-20.6 95% CI). After further subsetting low-risk cases to those with a definite MI (controls = 74, cases = 16), we found that the associations with the ACE DD genotype was also significant (P = 0.013, OR = 3.94, 1.28-12.2 95% CI). Comparable tests in the Framingham sample failed to support an association of these markers with CHD. In conclusion, within selected groups the ACE D and AGT 235T alleles are statistically associated with CHD and MI, and there is a synergistic interaction between the two alleles. These results and those from previous studies together suggest that the association of these two loci is neither strong nor consistent and involves a complex interaction among risk factors and genotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9034401     DOI: 10.1016/s1047-2797(96)00105-6

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  5 in total

Review 1.  Searching for the mountains of the moon: genome scans for atherosclerosis.

Authors:  Michael A Province
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

2.  Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.

Authors:  K G Nair; K K Shalia; T F Ashavaid; J J Dalal
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

3.  Association Between M235T-AGT and I/D-ACE Polymorphisms and Carotid Atheromatosis in Hypertensive Patients: A Cross-Sectional Study.

Authors:  Oana Mocan; Elena Buzdugan; Angela Cozma; Daniel Corneliu Leucuta; Dan Radulescu; Lucia Maria Procopciuc
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

4.  The M235T polymorphism in the AGT gene and CHD risk: evidence of a Hardy-Weinberg equilibrium violation and publication bias in a meta-analysis.

Authors:  Mohammad Hadi Zafarmand; Yvonne T van der Schouw; Diederick E Grobbee; Peter W de Leeuw; Michiel L Bots
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

5.  Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population.

Authors:  Mohammed Al-Najai; Paul Muiya; Asma I Tahir; Samar Elhawari; Daisy Gueco; Editha Andres; Nejat Mazhar; Nada Altassan; Maie Alshahid; Nduna Dzimiri
Journal:  BMC Cardiovasc Disord       Date:  2013-03-11       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.